On 28 MAY Inovio Pharmaceuticals Inc (NYSEMKT: INO) announced that VGX Animal Health, Inc, the company’s 90%-owned subsidiary, has now concluded the agreement for sale of its animal-health assets to the Plumb line Life Sciences of Korea. Inovio Pharmaceuticals Inc (NYSEMKT: INO) weekly performance is 8.13%. On last trading day company shares ended up $2.26. Analysts mean target price for the company is $4.80. Inovio Pharmaceuticals Inc (NYSEMKT: INO) distance from 50-day simple moving average (SMA50) is -16.68%.
On 27 MAY MacroGenics Inc (NASDAQ:MGNX) and Takeda Pharmaceutical Company Limited jointly announced that they have entered into an option agreement for the development and commercialization of MGD010. This product candidate incorporates MacroGenics’ proprietary platform for Dual-Affinity Re-Targeting (DART®) to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins. MGD010 is currently in pre-clinical development for the treatment of autoimmune diseases. MacroGenics Inc (NASDAQ:MGNX) shares advanced 5.14% in last trading session and ended the day on $20.44. MGNX return on assets is -5.50%. MacroGenics Inc (NASDAQ:MGNX) quarterly performance is -45.01%.
On 28 MAY Idera Pharmaceuticals Inc (NASDAQ:IDRA) announced that Company management will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014 at 8:30 a.m. EDT in New York City. Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares moved up 5.44% in last trading session and was closed at $3.10, while trading in range of $2.86 – $3.14. Idera Pharmaceuticals Inc (NASDAQ:IDRA) year to date (YTD) performance is -33.05%.
On 14 MAY Opexa Therapeutics Inc (NASDAQ:OPXA) reported financial results for the first quarter ended March 31, 2014.Interest expense of $1,635,254 for the three months ended March 31, 2013 was primarily related to the amortized debt discount and interest on both the July 25, 2012 convertible secured promissory notes and the January 23, 2013 convertible promissory notes and the amortization of the financing fees over the life of the notes. No interest expense was recorded for the three months ended March 31, 2014. Opexa Therapeutics Inc (NASDAQ:OPXA) reported a net loss for the three months ended March 31, 2014 of approximately $3.7 million, or $0.13 loss per share. Opexa Therapeutics Inc (NASDAQ:OPXA) ended the last trading day at $1.55. Company weekly volatility is calculated as 7.16% and price to cash ratio as 1.82. Opexa Therapeutics Inc (NASDAQ:OPXA) showed a positive weekly performance of 13.30%.
On 20 MAY Clovis Oncology Inc (NASDAQ:CLVS) announced after the close Monday that the FDA has granted Breakthrough Therapy Designation for its investigational agent CO-1686 as mono therapy for the treatment of second-line EGFR mutant NSCLC in patients with the T790M mutation. Clovis Oncology Inc (NASDAQ:CLVS) weekly performance is -5.72%. On last trading day company shares ended up $51.55. Analysts mean target price for the company is $98.63. Clovis Oncology Inc (NASDAQ:CLVS) distance from 50-day simple moving average (SMA50) is -15.07%.